Table 1.
Patient Characteristics
| Total # pts screened for BCR-ABL1 mutation1 | 284 |
|---|---|
| # Pts with BCR-ABL135ins | 64 (23%) |
|
| |
| Median age (range) | 51 (13–76) |
|
| |
| Males no. (%) | 36 (56%) |
|
| |
| CML phase at time of BCR-ABL135ins detection | |
|
| |
| Chronic | 45 (70%) |
|
| |
| Accelerated | 10 (15%) |
|
| |
| Blastic | 6 (9%) |
|
| |
| Other2 | 3 (5%) |
|
| |
| Time (mos) from diagnosis of CML to detection of BCR-ABL135ins | 23 (0–233) |
|
| |
| TKI used 1st line in chronic phase | |
|
| |
| Imatinib | 34 (76%) |
|
| |
| No response | 8 (22 %) |
| Response-progressed | 11 (33%) |
| Non compliant-progressed | 4 (11%) |
| Total # patients | 23(68%) |
| Toxicity-changed TKI | 7 (19%) |
| Remain on imatinib3 | 4 (11%) |
|
| |
| Dasatinib | 6 (13%) |
|
| |
| Nilotinib | 5 (11%) |
|
| |
| Ponatinib | 0 |
1
Between 8/1/2007–1/15/2014
2
Two pts had prior stem cell transplant, one had prior Philadelphia chromosome negative myeloproliferative neoplasm
3
One additional patient died from lung cancer while on imatinib